Analystreport

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com